No 04 2020

The Court of Appeal has overturned the District Court’s acquittal in the insider trading case involving events from the spring of 2019 and individuals from the company’s former management.

The company has announced the authorization of its Clinical Trial Application (CTA) from the regulatory authorities in four European countries under the European Union’s (EU) harmonised framework, for VIDAR-1, with Germany acting as the reference state.

The two companies have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology.

EsoBiotec is a biotechnology company focusing on in vivo cell therapies that has demonstrated promising early clinical activity.

Insights from ‘The Investors' Perspective’ Event

Charlotte Schönbeck has always been inquisitive and as sales specialist she gets to work with many different life science professionals. She learns something new from all of them by working together through their individual challenges to find the best solution. 

The company has been granted a patent by the European Patent Office (EPO) for GmPcides, a new class of synthetic antibacterials.